Citius oncology anticipates commercial launch of lymphir™ in 2025

Cranford, n.j. , june 17, 2025 /prnewswire/ -- citius oncology, inc. ("citius oncology") (nasdaq: ctor), the oncology-focused subsidiary of citius pharmaceuticals, inc. ("citius pharma") (nasdaq: ctxr), today announced that preparations for the commercial launch of lymphir™, an fda-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma (ctcl), are nearing completion.
CTXR Ratings Summary
CTXR Quant Ranking